Peptipedia
HormonalFDA ApprovedFDA Approved

Pegvisomant

Also known as Somavert

A GH receptor antagonist that blocks growth hormone action. Used for acromegaly when surgery and somatostatin analogs fail to normalize IGF-1. ~90% achieve normal IGF-1.

FDA Approved - Acromegaly
CompareFind Vendors

Regulatory Pathway

Preclinical
Phase I
Phase II
Phase III
Phase IV
Approved

Dosing Protocol

Typical Dose

10-30 mg daily

Frequency

Once daily

Duration

Long-term / chronic use

Community-reported dosing. Individual results vary. Not a medical recommendation.
Typical community protocol: 10-30 mg daily via Subcutaneous injection, Once daily. Dose range: 10-40 mg daily (40 mg loading dose). Duration: Long-term / chronic use.

Timing & Administration

Administer via Subcutaneous injection. Frequency: Once daily.

Mechanism of Action

Modified GH analog that binds GH receptors but prevents receptor activation and signaling. Directly blocks GH action rather than suppressing GH secretion, effectively normalizing IGF-1 levels.

Research Summary

Evidence level: fda approved. Clinical status: FDA Approved - Acromegaly.

Side Effects & Safety

Important Warnings

  • Liver toxicity monitoring required
  • Does not shrink tumors.
Infection
pain
nausea
injection site reactions
liver toxicity (rare but serious)
hypoglycemia in diabetics

References

No references available.

Related Peptides

Browse all →
OxytocinHormonal

A naturally occurring peptide hormone essential for social bonding, childbirth, and lactation. Under investigation for autism, anxiety, and social disorders.

View profile
GonadorelinHormonal

A synthetic version of gonadotropin-releasing hormone used diagnostically and therapeutically for reproductive conditions.

View profile
LeuprolideHormonal

A GnRH agonist suppressing testosterone and estrogen production, approved for prostate cancer, endometriosis, uterine fibroids, and precocious puberty.

View profile